Trial Profile
A Phase I Open-Label Trial Evaluating The Safety, Tolerability And Pharmacokinetics Of VB-1953 For The Treatment Of Patients With Moderate To Severe Facial Acne Vulgaris When Administered As A Topical Gel
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs VB 1953 (Primary)
- Indications Acne vulgaris
- Focus Adverse reactions; First in man; Pharmacokinetics
- 11 Jan 2020 Results assessing clinical pharmacokinetics, safety and exploratory efficacy study of a Topical Bactericidal VB-1953 published in the Clinical Drug Investigation
- 07 Feb 2017 Primary endpoint (Pharmacokinetics (plasma concentration less than 1 ng/ml)) has been met, according to top-line results published in a Vyome Biosciences Media Release.
- 07 Feb 2017 Top-Line results (n=12) published in a Vyome Biosciences Media Release.